La edición del ADN: ad portas de una revolución en la manipulación genética

Ithzayana Madariaga-Perpiñan; Juan Camilo Duque-Restrepo; Paola Ayala-Ramírez; Reggie García-Robles

doi:10.17533/udea.iatreia.56

Authors

Ithzayana Madariaga-Perpiñan Pontifical Xavierian University https://orcid.org/0000-0002-5042-9134
Juan Camilo Duque-Restrepo Pontifical Xavierian University https://orcid.org/0000-0002-1703-5926
Paola Ayala-Ramírez Pontifical Xavierian University https://orcid.org/0000-0002-5851-6638
Reggie García-Robles Pontifical Xavierian University https://orcid.org/0000-0002-6804-0979

DOI:

https://doi.org/10.17533/udea.iatreia.56

Keywords:

gene editing, genetic engineering, CRISPR-associated proteins, genetic therapy

Abstract

In biological sciences, genetic therapy constitutes a “trend topic” since its beginning. Development of new technologies in bioengineering as zinc-finger nucleases (ZFN), Transcription activator-like effector nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR – Cas9) opened doors to a countless number of possibilities in biology, as genetic edition. Last one consists in a direct genomic modification through nucleotide sequences “introduction” or “cleavage” on DNA strands.

Nowadays, its application is wide, since agroindustrial and pest control technologies to clinical area, with correcting mendelian diseases, modulating immunological receptors on infectious diseases, genetic modification in germ cells, among others. Nevertheless, since it’s discovered in 1987, CRISPR – Cas9 system has not been exempt from controversy in bioethical aspects, patent acquisition and even about effectiveness. Despite the difficulties and uncertainty that have arisen, the future of the system is promising for its simplicity and versatility.

|Abstract

= 1886 veces | PDF (ESPAÑOL (ESPAÑA))

= 1352 veces| | HTML (ESPAÑOL (ESPAÑA))

= 66 veces|

Downloads

Download data is not yet available.

Author Biographies

Ithzayana Madariaga-Perpiñan, Pontifical Xavierian University

Student of Medicine, Research Hotbed in Pharmacology.

Juan Camilo Duque-Restrepo, Pontifical Xavierian University

Student of Medicine, Research Hotbed in Pharmacology. Faculty of Medicine.

Paola Ayala-Ramírez, Pontifical Xavierian University

Professor. Institute of Human Genetics, Faculty of Medicine.

Reggie García-Robles, Pontifical Xavierian University

Professor. Department of Physiological Sciences, Faculty of Medicine.

References

(1) Dupuis MÈ, Villion M, Magadán AH, Moineau S. CRISPR-Cas and restriction-modification systems are compatible and increase phage resistance. Nat Commun. 2013;4:2087. DOI 10.1038/ncomms3087.

(2) Gaj T, Gersbach CA, Barbas CF 3dr. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):3974405. DOI 10.1016/j.tibtech.2013.04.004.

(3) Garcia-Robledo JE, Barrera MC, Tobón GJ. CRISPR/Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases. Int Rev Immunol. 2020;(39)1:11-20. DOI 10.1080/08830185.2019.1677645.

(4) Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331-8. DOI 10.1038/nature10886.

(5) Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490-507. DOI 10.1038/s41580-019-0131-5.

(6) Barrangou R, Birmingham A, Wiemann S, Beijersbergen RL, Hornung V, Smith AVB. Advances in CRISPR-Cas9 genome engineering: Lessons learned from RNA interference. Nucleic Acids Res. 2015;43(7):3407–19. DOI 10.1093/nar/gkv226.

(7) Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-21. DOI 10.1126/science.1225829.

(8) Jansen R, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002 Mar;43(6):1565-75. DOI 10.1046/j.1365-2958.2002.02839.x.

(9) Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-78. DOI 10.1016/j.cell.2014.05.010.

(10) Dance A. Core Concept: CRISPR gene editing. Proc Natl Acad Sci U S A. 2015;112(20):6245-6. DOI 10.1073/pnas.1503840112.

(11) Savić N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res. 2016;168:15-21. DOI 10.1016/j.trsl.2015.09.008.

(12) Weil PA. Genética molecular, DNA recombinante y tecnología genómica. In: Rondweel VW, Bender DA, Bothman KM, Kenelly PJ, Weil PA. Harper. Bioquímica ilustrada. 30 ed. Mexico, D.F: McGraw Hill; 2016.

(13) Xiong X, Chen M, Lim WA, Zhao D, Qi LS. CRISPR/Cas9 for Human Genome Engineering and Disease Research. Annu Rev Genomics Hum Genet. 2016;17:131-54. DOI 10.1146/annurev-genom-083115-022258.

(14) Redman M, King A, Watson C, King D. What is CRISPR/Cas9? Arch Dis Child Educ Pract Ed. 2016;101(4):213-5. DOI 10.1136/archdischild-2016-310459.

(15) Hille F, Charpentier E. CRISPR-Cas: biology , mechanisms and relevance. Philos Trans R Soc Lond B Biol Sci. 2016;371(1707). DOI 10.1098/rstb.2015.0496.

(16) Tian X, Gu T, Patel S, Bode AM, Lee MH, Dong Z. CRISPR/Cas9 - An evolving biological tool kit for cancer

biology and oncology. NPJ Precis Oncol. 2019 Mar 18;3:8. DOI 10.1038/s41698-019-0080-7.

(17) Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24:1526-33. DOI 10.1101/gr.173427.114.

(18) Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy

in mice by CRISPR/Cas9-mediated editing of germline DNA. Science. 2014;345(6201):1184-8. DOI 10.1126/science.1254445.

(19) Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Ccell. 2013;13(6):653-8. DOI 10.1016/j.stem.2013.11.002.

(20) Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014,159(2):440-55. DOI 10.1016/j.cell.2014.09.014.

(21) Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep. 2013;3:2510. DOI 10.1038/srep02510.

(22) Zhen S, Hua L, Takahashi Y, Narita S, Liu YH, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun. 2014;450(4):1422-6. DOI 10.1016/j.bbrc.2014.07.014.

(23) Wagner JC, Platt RJ, Goldfless SJ, Zhang F, Niles JC. Efficient CRISPR-Cas9-mediated genome editing in Plasmodium falciparum. Nat Methods. 2014;11:915-8. DOI 10.1038/nmeth.3063.

(24) Moreno AM, Mali P. Therapeutic genome engineering via CRISPR-Cas systems. Wiley Interdiscip Rev Syst Biol Med. 2017;9(4). DOI 10.1002/wsbm.1380.

(25) Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. FEBS J. 2014;281(23):5186-93. DOI 10.1111/febs.13110.

(26) Charlesworth C, Deshpande P, Dever D, Camarena J, Lemgart V, Cromer MK et al. Identification of preexisting

adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249-54. DOI 10.1038/s41591-018-0326-x.

(27) Kim EJ, Kang KH, Ju JH. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells. Korean J Intern Med. 2017;32(1):42–61. DOI 10.3904/kjim.2016.198.

(28) Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: A new and promising player in gene therapy. J Med Genet. 2015;52(5):289-96. DOI 10.1136/jmedgenet-2014-102968.

(29) Pellagatti A, Dolatshad H, Valletta S, Boultwood J. Application of CRISPR/Cas9 genome editing to the study and treatment of disease. Arch Toxicol. 2015;89(7):1023–34. DOI 10.1007/s00204-015-1504-y.

(30) Castillo A. Edición de genes para el tratamiento del cáncer de pulmón (CRISPR-Cas9). Colomb Med. 2016;47:178-80.

(31) Ledford H. Titanic clash over CRISPR patents turns ugly. Nature. 2016;537(7621):460–1. DOI 10.1038/537460a.

(32) Du D, Qi LS. CRISPR Technology for Genome Activation and Repression in Mammalian Cells. Cold Spring Harb Protoc. 2016 Jan 4;2016(1). DOI 10.1101/pdb.prot090175.

(33) Huang Y, Porter A, Zhang Y, Barrangou R. Collaborative networks in gene editing. Nat Biotechnol. 2019 Oct;37(10):1107-9. DOI 10.1038/s41587-019-0275-z.

(34) Im W, Moon J, Kim M. Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders. J Mov Disord. 2016;9(3):136-43. DOI 10.14802/jmd.16029.

(35) Cyranoski D. The CRISPR-baby scandal: what’s next for human gene-editing. Nature. 2019 Feb;566(7745):440-2. DOI 10.1038/d41586-019-00673-1.

(36) Reardon S. Gene edits to ‘CRISPR babies’ might have shortened their life expectancy. Nature. 2019 Jun;570(7759):16-7. DOI 10.1038/d41586-019-01739-w.

(37) Wei X, Nielsen R. CCR5-Δ32 is deleterious in the homozygous state in humans. Nat Med. 2019 Jun;25(6):909-

DOI 10.1038/s41591-019-0459-6.

(38) Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-57. DOI 10.1038/s41586-019-1711-4.

(39) Bellver V. La revolución de la edición genética mediante crispr-cas9 y los desafíos éticos y regulatorios que comporta. Cuad Bioet. 2016;27(2):223-39.